To explore the relationship between hypoperfusion and white matter injury in cognitive impairment of cerebral small vessel disease by ASL and DTI

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057336

Enrollment

Unknown

Registered

2022-03-08

Start date

2022-03-09

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral small vessel disease (CSVD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It conforms to the definition of possible vasogenic white matter hyperintensity in the imaging diagnostic criteria of cerebral small vessel disease; 2. Fazekas>=2 and >=1 vascular risk factors (hypertension, diabetes, current smoking); 3. Age >=65; 4. Han Nationality; 5. Right-handed; 6. Hamilton Depression Scale (HAMD) score <=17; 7. Relatively independent daily life (modified Rankin<=2); 8. No gait disorder, and the risk assessment of the Timed Up and Go Test (TUG) <=2; 9. The patient or legal representative agrees to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Cognitive impairment is not significantly associated with white matter hyperintensity, such as stroke, Alzheimer's disease, Parkinson's disease, etc.; 2. Previous history of stroke, including cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage; 3. The intracranial and extracranial vascular stenosis =50%, which is evaluated by MRA, CTA, DSA, and other imaging techniques; 4. White matter hyperintensity are caused by non-vascular factors, such as sarcoidosis, multiple sclerosis, toxication, leukodystrophy, radiation encephalopathy, etc. 5. Single-gene genetic diseases related to small vessels disease, such as CADASIL, CAA, etc.; 6. MRI show the temporal lobe atrophy, and the scores of Medial Temporal lobe Atrophy (MTA)> 2; 7. Comorbidity with alzheimer's disease, frontotemporal dementia, Lewy body dementia, Parkinson's disease, and other neurodegenerative diseases; 8. Comorbidity with brain tumor, epilepsy, brain trauma, and other neurological diseases or mental diseases; 9. Comorbidity with obvious abnormalities in motor, sensory, language, emotion, audio-visual and other neurological; 10. Patients cannot cooperate with relevant examinations or neurological function assessment; 11. Patients have received cardiac pacemaker surgery, coronary artery stand interpolation, coronary artery bypass surgery, or other metal objects in their bodies; 12. Unable to complete MRI examination for more than 30 minutes; 13. Comorbidity with severe disease, such as malignant tumor, the expected survival time is less than 2 years.

Design outcomes

Primary

Measure	Time frame
Diffusion Tensor Imaging parameters;Arterial Spin Labeling parameters;	—

Secondary

Measure	Time frame
Mini-mental State Examination,MMSE;Trail Making Test A, TMT-A;Trail Making Test B, TMT-B;Boston Naming Test 2, BNT-2;Hopkins Verbal Learning Test, HVLT;Clock Drawing Test, CDT;Instrumental Activities of Daily Living, IADL;	—

Countries

China

Contacts

Public ContactYao Xie

Hunan Academy of Traditional Chinese Medicine Affiliated Hospital

xieyaohing@163.com+86 15974271324

Outcome results